TY - JOUR
T1 - Dynamic landscape and regulation of RNA editing in mammals
AU - GTEx Consortium
AU - Tan, Meng How
AU - Li, Qin
AU - Shanmugam, Raghuvaran
AU - Piskol, Robert
AU - Kohler, Jennefer
AU - Young, Amy N.
AU - Liu, Kaiwen Ivy
AU - Zhang, Rui
AU - Ramaswami, Gokul
AU - Ariyoshi, Kentaro
AU - Gupte, Ankita
AU - Keegan, Liam P.
AU - George, Cyril X.
AU - Ramu, Avinash
AU - Huang, Ni
AU - Pollina, Elizabeth A.
AU - Leeman, Dena S.
AU - Rustighi, Alessandra
AU - Goh, Y. P.Sharon
AU - Aguet, François
AU - Ardlie, Kristin G.
AU - Cummings, Beryl B.
AU - Gelfand, Ellen T.
AU - Getz, Gad
AU - Hadley, Kane
AU - Handsaker, Robert E.
AU - Huang, Katherine H.
AU - Kashin, Seva
AU - Karczewski, Konrad J.
AU - Lek, Monkol
AU - Li, Xiao
AU - MacArthur, Daniel G.
AU - Nedzel, Jared L.
AU - Nguyen, Duyen T.
AU - Noble, Michael S.
AU - Segrè, Ayellet V.
AU - Trowbridge, Casandra A.
AU - Tukiainen, Taru
AU - Abell, Nathan S.
AU - Balliu, Brunilda
AU - Barshir, Ruth
AU - Basha, Omer
AU - Battle, Alexis
AU - Bogu, Gireesh K.
AU - Brown, Andrew
AU - Brown, Christopher D.
AU - Castel, Stephane E.
AU - Chen, Lin S.
AU - Chiang, Colby
AU - Conrad, Donald F.
N1 - Funding Information:
was supported by the Common Fund of the Office of the Director of the NIH. Additional funds were provided by the NCI, NHGRI, NHLBI, NIDA, NIMH and NINDS. Donors were enrolled at Biospecimen Source Sites funded by NCI\SAIC-Frederick, Inc. (SAIC-F) subcontracts to the National Disease Research Interchange (10XS170), Roswell Park Cancer Institute (10XS171), and Science Care, Inc. (X10S172). The Laboratory, Data Analysis, and Coordinating Center (LDACC) was funded through a contract (HHSN268201000029C) to The Broad Institute, Inc. Biorepository operations were funded through an SAIC-F subcontract to Van Andel Institute (10ST1035). Additional data repository and project management were provided by SAIC-F (HHSN261200800001E). The Brain Bank was supported by a supplement to University of Miami grants DA006227 and DA033684 and to contract N01MH000028. Statistical Methods development grants were made to the University of Geneva (MH090941 and MH101814), the University of Chicago (MH090951, MH090937, MH101820 and MH101825), the University of North Carolina-Chapel Hill (MH090936 and MH101819), Harvard University (MH090948), Stanford University (MH101782), Washington University St Louis (MH101810), and the University of Pennsylvania (MH101822).
Funding Information:
Acknowledgements We thank C. Mason and L. Pipes for help with nonhuman primate RNA-seq data, Y. Hu, P. Sahbaie, A. Chang, K. McGowan and R. Hannibal for technical assistance, and J. Baker and H. H. Ng for use of laboratory resources. We also thank A. Fire, Y. Wan, K. W. K. Sung, W. Zhai, S. Prabhakar,and members of the Li and Tan laboratories for discussions and critical reading of the manuscript. This work is supported by National Institutes of Health (NIH) grants R01GM102484, R01GM124215 and U01HG007593 (J.B.L.), R01GM040536 (K.N.), R01CA175058 (K.N.), and R01AI012520 (C.E.S.), Ellison Medical Foundation (J.B.L. and K.N.), Stanford University Department of Genetics (J.B.L.), Genome Institute of Singapore (M.H.T.), Nanyang Technological University School of Chemical and Biomedical Engineering (M.H.T.), National Medical Research Council OFIRG15nov151 (M.H.T.), the Commonwealth Universal Research Enhancement Program, Pennsylvania Department of Health (K.N.), MRC and European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement No 621368 (M.A.O’C.), NHMRC project grant 1102006 (C.W. and J.B.L.), Italian Health Ministry (RF-2011-02346976) and the Italian Association for Cancer Research (AIRC) Special Program Molecular Clinical Oncology ‘5 per mille’ (grant no. 10016), AIRC IG (grant no. 17659) (G.D.S.), the Cariplo Foundation (grant no. 2014-0812) (G.D.S.), Stanford Graduate Fellowship (G.R.), German Academic Exchange Service research fellowship (R.P.) and Stanford University School of Medicine Dean’s Fellowship (Q.L., R.P. and R.Z.). The Genotype-Tissue Expression (GTEx) project
Publisher Copyright:
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
PY - 2017/10/11
Y1 - 2017/10/11
N2 - Adenosine-to-inosine (A-to-I) RNA editing is a conserved posttranscriptional mechanism mediated by ADAR enzymes that diversifies the transcriptome by altering selected nucleotides in RNA molecules1. Although many editing sites have recently been discovered2-7, the extent to which most sites are edited and how the editing is regulated in different biological contexts are not fully understood8-10. Here we report dynamic spatiotemporal patterns and new regulators of RNA editing, discovered through an extensive profiling of A-to-I RNA editing in 8,551 human samples (representing 53 body sites from 552 individuals) from the Genotype-Tissue Expression (GTEx) project and in hundreds of other primate and mouse samples. We show that editing levels in non-repetitive coding regions vary more between tissues than editing levels in repetitive regions. Globally, ADAR1 is the primary editor of repetitive sites and ADAR2 is the primary editor of nonrepetitive coding sites, whereas the catalytically inactive ADAR3 predominantly acts as an inhibitor of editing. Cross-species analysis of RNA editing in several tissues revealed that species, rather than tissue type, is the primary determinant of editing levels, suggesting stronger cis-directed regulation of RNA editing for most sites, although the small set of conserved coding sites is under stronger trans-regulation. In addition, we curated an extensive set of ADAR1 and ADAR2 targets and showed that many editing sites display distinct tissue-specific regulation by the ADAR enzymes in vivo. Further analysis of the GTEx data revealed several potential regulators of editing, such as AIMP2, which reduces editing in muscles by enhancing the degradation of the ADAR proteins. Collectively, our work provides insights into the complex cis-and trans-regulation of A-to-I editing.
AB - Adenosine-to-inosine (A-to-I) RNA editing is a conserved posttranscriptional mechanism mediated by ADAR enzymes that diversifies the transcriptome by altering selected nucleotides in RNA molecules1. Although many editing sites have recently been discovered2-7, the extent to which most sites are edited and how the editing is regulated in different biological contexts are not fully understood8-10. Here we report dynamic spatiotemporal patterns and new regulators of RNA editing, discovered through an extensive profiling of A-to-I RNA editing in 8,551 human samples (representing 53 body sites from 552 individuals) from the Genotype-Tissue Expression (GTEx) project and in hundreds of other primate and mouse samples. We show that editing levels in non-repetitive coding regions vary more between tissues than editing levels in repetitive regions. Globally, ADAR1 is the primary editor of repetitive sites and ADAR2 is the primary editor of nonrepetitive coding sites, whereas the catalytically inactive ADAR3 predominantly acts as an inhibitor of editing. Cross-species analysis of RNA editing in several tissues revealed that species, rather than tissue type, is the primary determinant of editing levels, suggesting stronger cis-directed regulation of RNA editing for most sites, although the small set of conserved coding sites is under stronger trans-regulation. In addition, we curated an extensive set of ADAR1 and ADAR2 targets and showed that many editing sites display distinct tissue-specific regulation by the ADAR enzymes in vivo. Further analysis of the GTEx data revealed several potential regulators of editing, such as AIMP2, which reduces editing in muscles by enhancing the degradation of the ADAR proteins. Collectively, our work provides insights into the complex cis-and trans-regulation of A-to-I editing.
UR - http://www.scopus.com/inward/record.url?scp=85031298074&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031298074&partnerID=8YFLogxK
U2 - 10.1038/nature24041
DO - 10.1038/nature24041
M3 - Article
C2 - 29022589
AN - SCOPUS:85031298074
SN - 0028-0836
VL - 550
SP - 249
EP - 254
JO - Nature
JF - Nature
IS - 7675
ER -